Press Release

Sanofi India delivers strong Q2 2026 performance, Led by double digit growth in Diabetes Portfolio and a Robust Profit Momentum

Mumbai, August 4th, 2026

Sanofi India Limited announced its financial results for the quarter ended on June 30th, 2026, reporting **domestic net sales** growth of **8%** and total net sales growth of **6%** compared to the second quarter of 2025.

The **Insulin portfolio** continued its strong trajectory, delivering **double-digit growth of 14%** for the second consecutive quarter, reinforcing Sanofi's leadership position in the basal analog market with a **58% value market share and 61% volume market share***. Growth was powered by Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®, the premium offering in the premix diabetes space.

The **public sector business** accelerated by **70%**, with the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, further strengthening Sanofi's footprint in the diabetes injectable space.

Strategic partnerships in Cardiovascular, Oral anti-Diabetes and Central Nervous System segments have established a strong foundation, meeting expectations for market reach expansion. **Partnership revenues grew 2%** in Q2 2026, with continued return on investment from an expanded commercial footprint

Export sales remained broadly stable, demonstrating the resilience of Sanofi India's international operations amid global headwinds.

Profits before tax and exceptional items increased 19% to INR 112 crores, compared to INR 94 crores in the second quarter 2025. Profit before tax as a percentage of net sales improved to **27% in Q2 2026**, up from 24% in Q2 2025.

This improvement reflects a favorable product mix and disciplined cost management through operational efficiencies, with **operating expenses** (employee cost + other expenses) **declining 5%** compared to the second quarter of 2025.

Deepak Arora
Managing Director

"Q2 2026 marks another chapter of purposeful, profitable growth for Sanofi India, with our diabetes portfolio posting double-digit growth for the second consecutive quarter and profit before tax growing 19%. These results reflect the discipline and momentum we have built across the business.

Our acceleration in the public sector demonstrates that we are not just growing; we are broadening access to innovative therapies across the country. With a 57.3% value share in the diabetes injectable segment, a modernized go-to-market model, and a business that has grown 17% in the first half of 2026, the foundation for sustainable, long-term value creation is firmly in place.

As we mark seven decades of serving Indian patients, guided by our purpose to chase the miracles of science, we remain focused on capturing the immense growth opportunity that India's diabetes landscape presents."

* Source for market share: IQVIA MAT June 2026

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices from 2019-2024, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/india, LinkedIn and X.

Media Relations
Vinifer Gandhi | vinifer.gandhi@sanofi.com